Fatty acid dietary supplement for chronic low back pain

The effectiveness of cetylated fatty acids on pain and mobility in patients with chronic low back pain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16509365

Enrollment

Registered

2022-04-28

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain Musculoskeletal Diseases

Interventions

Patients with chronic low back pain will take 2 capsules twice a day of LipoCet (Cetylated Fatty Acids) 300mg for 1 month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 21 years of age with low back pain for more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Patients currently on narcotic pain medication 2. Patients unwilling to follow the study protocol 3. Pregnant or currently breastfeeding 4. Patients with low back pain from a traumatic injury 5. Patients currently using a pain patch (e.g. lidocaine)

Design outcomes

Primary

Measure	Time frame
Patients' functionality based on the Oswestry Low Back Pain Disability Questionnaire (ODI) evaluated pre-treatment and after 1 month of initiating the dietary supplement.	—

Secondary

Measure	Time frame
1. Low back pain based on the Numeric Pain Rating Scale (0-10) evaluated pre-treatment and after 1 month of initiating the dietary supplement. 2. Adverse effects related to the dietary supplement evaluated after 1 month of the treatment using a questionnaire.	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026